TLDR The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
The document reports a study on the effects of the antiandrogen drug enzalutamide (ENZA) on the protein TMPRSS2, which is known to facilitate the entry of SARS-CoV-2 into cells. The study found that ENZA can downregulate TMPRSS2 levels in human lung cells and mouse lung tissue, leading to a significant decrease in SARS-CoV-2 cellular entry and infection. In vivo experiments with mice and in vitro experiments with A549 lung cells expressing the ACE2 receptor showed that ENZA and another antiandrogen, bicalutamide (BIC), significantly reduced viral entry and infection. The study supports the hypothesis that androgen receptor activation increases TMPRSS2 levels and suggests that antiandrogens could be a potential therapeutic option for COVID-19. The findings also highlight the potential for antiandrogen therapy to be well-tolerated in both men and women, proposing clinical trials to assess the efficacy of antiandrogens in treating COVID-19.
139 citations,
December 2020 in “Cell Stem Cell” Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
119 citations,
May 2020 in “Journal of The American Academy of Dermatology” Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
71 citations,
April 2020 in “Journal of Cosmetic Dermatology” Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
134 citations,
April 2020 in “Journal of Cosmetic Dermatology” Male pattern hair loss could hint at androgens affecting COVID-19 severity.
17 citations,
October 2013 in “Plastic and reconstructive surgery. Global open” Male pattern baldness may be caused by scalp pressure on hair follicles, which increases with age and leads to a cycle of hair loss. This process is not directly determined by genes.
89 citations,
August 2013 in “PloS one” Androgen receptors are active in many tissues of both male and female mice, not just reproductive organs.
10 citations,
October 1988 in “Clinics in dermatology” Topical antiandrogens might be a good option for male-pattern baldness with fewer side effects, but more research is needed to confirm their safety and effectiveness.
97 citations,
November 1986 in “Journal of Steroid Biochemistry” Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.
